Examining medicine shortages and their consequences through economic, clinical, and economic lens
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts
Cemiplimab Cervical Cancer Access Navigating Treatment and Value
Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...
Shifting Perspectives on Pharmaceutical Innovation ROI as Socioeconomic Investment
Pharmaceutical innovation ROI is shifting from a narrow budget metric to a powerful indicator of societal return. Between 2014 and 2024, a 3.1-year rise in utilization-weighted mean drug vintage across 29 European countries prevented 1.83 million years of life lost before age 85 and saved 20.9 mi...
Pharmaceutical Innovation Benefits Driving Socioeconomic Returns in Europe
Pharmaceutical innovation benefits extend well beyond clinical gains, delivering €5.67 in socioeconomic value for every additional euro spent on newer therapies across 29 European countries from 2014 to 2024. By reducing premature mortality, cutting hospital stays, and increasing workforce partic...